Scott Winder joins RNA to expand its Life Science Tax and Financial Reporting Valuation Group
RNA Advisors, LLC, a leading valuation and strategic advisory services firm focused exclusively in life sciences and healthcare technology, announced today that Scott Winder has joined the firm’s Valuation Advisory Services Group as a Managing Director. Based in the San Francisco Bay Area, Mr. Winder will work with RNA’s other senior officers to deliver a […]
Client Success: Healthcare Transaction Support to Assess Value from Different Perspectives
By Jeff Williamson THE SITUATION: A healthcare company with a portfolio of products in development for treating cardiac conditions was fielding investor interest for a potential acquisition. The company wanted to weigh the relative merits of raising additional equity financing versus exploring multiple M&A offers, as these initial discussions indicated a price range that did […]
Client Success: Mandatory Adoption of ASC 842 – Incremental Borrowing Rate Analysis for Private Biotech
By Jeff Suchocki, CFA The Situation: Adoption of ASC 842 – Lease Accounting is mandatory for all private companies for fiscal years beginning after December 15, 2021. To comply with this mandatory adoption requirement, a privately held, clinical stage biotech company needed to understand a reasonable discount rate for multiple lease agreements. The company requested […]
Client Success: Navigating Strategic Investment in Healthcare Technology
THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The company received from the strategic partner a “low-ball” valuation. The company’s management team and board […]
Why Valuation Matters in Early-Stage Life Sciences
“Value”, the outcome of a thorough valuation analysis, is ultimately what parties agree to. Sometimes this seems a rational outcome, other times an irrational one. The reality is that a life sciences or healthcare technology company’s valuation often results from the ability or inability to create an effective bidding process and to persuade/anchor a strategic […]
Client Success: Derivatives Valuation for pre-IPO Biotechnology Company
THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo […]
Client Success: Portfolio Valuation for LPs of $1B + Healthcare-Focused PE Firm
THE PROBLEM: Two of the largest pension funds in the world required an independent valuation assessment of the portfolio of a multi-billion dollar life science/ healthcare private equity fund. THE SOLUTION: Robust research, forecasting, modeling, comp analysis and valuation analytics to determine reasonableness of value indications. “We love working with you. You actually know what […]
